Objectives We investigated whether serum tumor markers (STMs) represent a valuable
noninvasive tool to predict epidermal growth factor receptor (EGFR) mutations in non-small …

Purpose This preplanned exploratory analysis was conducted to reveal the true status of
correlation between tissue and plasma detection for early-stage non-small cell lung cancer …

Background: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor
(EGFR) represent novel, effective tools in the management of advanced-stage non-small cell …

Simple Summary Patients with non-small cell lung cancer with an activating EGFR mutation
in the tumor, are treated with targeted therapy against this mutation. In the end, all patients …

Objective The aim of this study was to investigate the correlation between the efficacy of
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and circulating tumor …

Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors
(TKI) Treatment in Non-Small Cell Lung Cancer - PMC Back to Top Skip to main content NIH …

Purpose The role of serum tumor markers (STMs) in the modern management of epidermal
growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in lung …

Objective To study the clinical significance of serum epidermal growth factor receptor
(EGFR) gene mutation and serum tumor markers in the prediction of tyrosine kinase inhibitor …

Background A critical point in designing clinical trials comparing chemotherapy with
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non …

The aim of this study has been to investigate the potential of serum biomarkers used in
clinical practice (CEA, CYFRA 21–1, SCC) together with the serum epidermal growth factor …